Global Markets Directs, 'T-Cell Lymphomas - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. T-Cell Lymphomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


[b]Scope[/b]

* A snapshot of the global therapeutic scenario for T-Cell Lymphomas.
* A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the T-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.


[b]Reasons to buy[/b]

* Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


[b]To order this report:[/b]

Email: [email protected]
US: +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.com


[b]RELATED LINK:[/b]

http://www.researchonglobalmarkets.com/t-cell-lymphomas-pipeline-review-h2-2013.html